Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study

Kawata, Ariane K.; Shah, Neel; Poon, Jiat Ling; Shaffer, Shannon; Sapra, Sandhya; Wilcox, Teresa K.; Shah, Shweta; Tepper, Stewart J.; Dodick, David W.; Lipton, Richard B.

doi:10.1111/head.14053

Cited by 29 publications

(30 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These low rates of persistence may lead to increased burden of migraine as healthcare resource utilization has been shown to be greater among individuals who failed multiple migraine preventive therapies [ 10 ]. Importantly, there may also be substantial health risks when patients decide to alter their prescribed treatment plan without consulting their healthcare provider [ 11 ]. Thus, more effective and tolerable preventive treatments may promote wider use with the potential to reduce the burden of migraine to individuals and society.…”

Section: Introductionmentioning

confidence: 99%

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

et al. 2021

View full text Add to dashboard Cite

Introduction: Erenumab is indicated for migraine preventive treatment in adults. The objective of this study was to provide descriptive information on real-world use of erenumab including patient profile and treatment patterns. Methods: We completed a retrospective review of US data (through May 2019) from the IBM MarketScan Ò Early View Databases, identifying adult patients newly treated with erenumab with a migraine claim in the year prior to first erenumab claim (index) and at least 1 year of continuous pre-index medical and pharmacy insurance coverage, to assess pre-and post-erenumab migraine characteristics, comorbidities, healthcare resource utilization, and associated costs. All data were summarized using descriptive statistics. Results: A total of 9753 patients met inclusion criteria. The average (SD) age was 46 (12) years,

show abstract

Section: Introductionmentioning

confidence: 99%

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Pivotal trials have demonstrated that both topiramate and erenumab are effective in migraine prevention ( 5 – 8 , 15 , 18 , 20 – 22 ). However, interventional, and observational studies have revealed that discontinuation rates are relatively high for topiramate ( 1 , 18 , 22 , 23 ). Tolerability is a prerequisite for an effective migraine drug to achieve meaningful improvement in a broad migraine population.…”

Section: Discussionmentioning

confidence: 99%

“…In migraine prophylaxis, tolerability is a major contributing factor to therapeutic success. Still, a recently published study shows that 28.2% of US migraine patients discontinue treatment within 6 months, mostly due to side effects ( 1 ).…”

Section: Introductionmentioning

confidence: 99%

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

Reuter

Ehrlich

Gendolla³

et al. 2021

Cephalalgia

View full text Add to dashboard Cite

Background We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to the calcitonin gene-related peptide receptor, to topiramate for migraine prophylaxis in adults. Methods HER-MES was a 24-week, randomised, double-blind, double-dummy, controlled trial conducted in 82 sites in Germany. Patients with ≥4 migraine days per month and naïve to study drugs were randomly assigned (1:1) to either subcutaneous erenumab (70 or 140 mg/month) plus topiramate placebo (erenumab group) or oral topiramate at the individual dose with optimal efficacy (50–100 mg/day) plus erenumab placebo (topiramate group). The primary endpoint was medication discontinuation due to an adverse event during the double-blind phase. The proportion of patients that achieved ≥50% reduction from baseline in monthly migraine days during the last 3 months of the double-blind phase was a secondary endpoint. Results Seven hundred and seventy-seven patients were randomised (from 22 February 2019 to 29 July, 2020) and 95.1% completed the study. In the erenumab group, 10.6% discontinued medication due to adverse events compared to 38.9% in the topiramate group (odds ratio, 0.19; 95% confidence interval 0.13–0.27; p < 0.001). Significantly more patients achieved a ≥50% reduction in monthly migraine days from baseline with erenumab (55.4% vs. 31.2%; odds ratio 2.76; 95% confidence interval 2.06–3.71; p < 0.001). No new safety signals occurred. Conclusions Erenumab demonstrated a favourable tolerability and efficacy profile compared to topiramate. Trial registration: ClinicalTrials.gov NCT03828539, URL: https://clinicaltrials.gov/ct2/show/NCT03828539

show abstract

“…In contrast, prophylactic treatment has relied on drugs originally developed for other disorders, such as antihypertensive or antiepileptic drugs. Unfortunately, all of these compounds are only moderately effective, with side effects that limit adherence (Kawata et al, 2021). The identification of CGRP as causative in migraine events has led to the development of different therapeutic strategies to specifically treat or prevent migraine.…”

Section: Targeting Cgrp To Treat Migrainementioning

confidence: 99%

Neurogenic inflammation as a novel treatment target for chronic pain syndromes

Seidel¹,

Hügle²,

Morlion³

et al. 2022

Experimental Neurology

View full text Add to dashboard Cite

Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 29 publications

References 32 publications

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

Neurogenic inflammation as a novel treatment target for chronic pain syndromes

Contact Info

Product

Resources

About